Hence, it is essential to acquire a better understanding of the pathophysiology of GRPR-positive cancers and, especially, the dependence of GRPR expression density on disease type, stage, coexpression of other biomolecular targets, individual patient biochemical background, and previous or even concomitant therapies. This evidence concerns the gene GRPR and cancer.